Clinical characteristics and outcome of hospitalized COVID-19 patients with diabetes: A single-center, retrospective study in Iran.

AIM: To describe the epidemiological and clinical characteristics along with outcomes of hospitalized Coronavirus Disease 2019 (COVID-19) patients with and without diabetes. METHODS: This retrospective, single-center study included 595 consecutive hospitalized patients with confirmed COVID-19 at Baqiyatallah Hospital in Tehran, Iran, from February 26, 2020 to March 26, 2020. Demographic data, clinical, laboratory, and radiological findings were collected and compared between patients based on diabetes status. Complications and clinical outcomes were followed up until April 4, 2020. RESULTS: From among the 595 hospitalized patients with COVID-19, the median age was 55 years and 401 (67.4%) were male. The most common symptoms included fever (419 [70.4%]), dry cough (368 [61.8%]) and dyspnea (363 [61%]). A total of 148 patients (24.9%) had diabetes, and compared with patients without diabetes, these patients had more comorbidities (eg, hypertension [48.6% vs. 22.3%; P < 0.001]); had higher levels of white blood cell count, neutrophil count, C-reactive protein, erythrocyte sedimentation rate and blood urea nitrogen, and had a higher proportion of patchy ground-glass opacity in chest computed tomography findings (52.7% vs. 25.7%; P < 0.001). Significantly, patients with diabetes had more complications and needed more respiratory support than those without diabetes (P < 0.001). At the end of the follow-up, treatment failure and death was significantly higher in patients with diabetes compared to those without diabetes (17.8% vs. 8.7%; P = 0.003). CONCLUSION: COVID-19 patients with diabetes are at a higher risk of complications and a higher in-hospital mortality during hospitalization. Diabetes status of COVID-19 patients and frequent monitoring of glycemia would be helpful to prevent deteriorating clinical conditions.

Electrospun Schizophyllan/polyvinyl alcohol blend nanofibrous scaffold as potential wound healing.

In this study, aqueous Schizophyllan (SPG) (1.5 w/v%) was mixed with aqueous polyvinyl alcohol (PVA) (10 w/v%) at various volume ratios and electrospun to prepare nanofibers. The fiber diameter was decreased by increasing the SPG content. A reliable linear relationship (p < 0.01) was established between the solution properties and fiber diameter. Contiguous, bead-free, and smooth fibers were obtained when the SPG/PVA ratios were 20:80, 30:70, and 40:60. FT-IR spectra, SEM images, tensile testing, swelling ratios, and water contact angle were utilized to characterize this glutaraldehyde (Glu) vapor cross-linked nanofibers in order to analyze the morphology, functional groups, mechanical attributes, hydrophilicity, and humidity of the nanofibers for skin tissue regeneration. Furthermore, the cell culture that was studied by the use of fibroblast (L929) cells showed that these SPG-based nanofibrous scaffolds could generate the improved cell adhesion. In conclusion, it was observed that SPG/PVA nanofiber mat in a volume ratio of 20:80 after 3 day was a suitable material for improving the wound healing, as it could increase cell proliferation and migration that possessed fiber diameter. The characteristics of this nanofiber were 267 nm, contact angle of 47.75°, good swelling behavior (289%), the ultimate strength of 6.513 MPa, Young modulus of 2.665 MPa, and cell viability of 150%.

Bio-barcode technology for detection of Staphylococcus aureus protein A based on gold and iron nanoparticles.

S. aureus is one of important causes of disease, food poisoning in humans and animals. The generally methods for detection of S. aureus is time consuming. Therefore, a new method is necessary for rapid, sensitive and specific diagnosis of S. aureus. In the present study, two probes and a Bio-barcode DNA were designed for detection of S. aureus (Protein A). Firstly, magnetic nanoparticle (MNPs) and gold nanoparticle (AuNPs) were synthesized at 80 °C and 100 °C, respectively. The AuNPs and the MNPs were functionalized with probe1, Bio-barcode DNA and probe2, respectively. Target DNA was added into the nanomaterial's system containing bio-barcode DNA-AuNPs-probe1 and probe2-MNPs to formed bio-barcode DNA-AuNPs-probe1-target DNA-probe2-MNPs complex. The bio-barcode DNA-AuNPs-probe1-target DNA-probe2-MNPs complex was separated with magnetic field. Finally, the bio-barcode DNA was released from surface of complex using DTT (0.8 M) and there was isolated of nanoparticles by magnetic field and centrifuge. The fluorescence intensity of bio-barcode DNA was measured in different concentrations of S. aureus (101 to 108 CFU mL-1) by fluorescence spectrophotometry. The results showed that standard curve was linearly from 102 to 107 CFU mL-1. Limit of detection of bio-barcode assay for both PBS and real samples was 86 CFU mL-1.

CdS nanocrystals/graphene oxide-AuNPs based electrochemiluminescence immunosensor in sensitive quantification of a cancer biomarker: p53.

An ultrahigh sensitive, simple and reliable Electrochemiluminescence (ECL) immunosensor for selective quantification of p53 protein was designed according to the enhancement effects of AuNPs on ECL emission of CdS nanocrystals (CdS NCs). CdS NCs were immobilized on the glassy carbon electrode and AuNPs introduced to the process through formation of a sandwich-type immunocomplex between first anti-p53/p53/ secondary anti-p53. ECL of CdS NCs firstly evoked the SPR of AuNPs which in return amplified the CdS NCs ECL intensity. By using graphene oxide in immunosensor fabrication procedure, and attaching more AuNPs on the surface of the electrode, the ECL intensity was further increased resulting in much higher sensitivity. After applying the optimum conditions, the linear range of the developed immunosensor was found between 20 and 1000 fg/ml with a calculated limit of detection of 4 fg/ml. Moreover, the interference, reproducibility and storage stability studies of the immunosensor were investigated. Finally, immunosensor's authenticity was evaluated by detecting the p53 protein in human spikes which offers it as a potential in early detection of cancer, monitoring the cancer progress and clinical prognosis.

Modified PLGA nanofibers as a nerve regenerator with Schwann cells.

Polylactide-co-glycolide acid (PLGA) is known as a biodegradable and biocompatible polymer. This polymer has been highly used in tissue engineering. In this study, the biological behavior of Schwann cells (Rat) was investigated in co-culture with L lysine/gelatine coated PLGA nano-fiber. In this study, PLGA was dissolved in a hexafluoro propanol based solvent and nanofiber prepared by an electronic method. They were coated with gelatin and poly-L-lysine individually. These polymer properties were investigated by Scanning Electron Microscopy (SEM) analysis and contact angle measurement. After extraction of rat Schwann cells, the cells were cultured in three groups of nano-fiber; nano-fiber PLGA, nano-fiber gelatine coated PLGA and nano-fiber poly-L-lysine coated PLGA. Cell death and Cell proliferation were evaluated by Acridine orange staining (living cell with a green nucleus and dead cell with an orange nucleus) and morphology was investigated by SEM in 2, 4 and 6 days. The diameter of electronic nanofiber PLGA was between 270 to 700 nm. Average contact angles of PLGA, PLGA coated with gelatine, coated with poly-L-lysine and PLGA were 40.12, 64.58 and 107.66degrees, respectively. The findings showed a significant reduction of cell proliferation in PLGA nanofiber ( it was important than PLGA without nano-fiber (P <0.05)). But, this amount was increased in nanofiber which coated with poly-L-lysine and gelatine. PLGA nanofiber-poly-L-lysine was more biocompatible than PLGA nanofiber-gelatine and this comparison was done with rat Schwann cells.

Using gold nanoparticles in diagnosis and treatment of melanoma cancer.

Several studies have been devoted to clear functionalization of gold nanoparticles (AuNPs) in different fields such as cellular and molecular biology, microbiology, immunology and physiology. In line with the high diagnostic value of AuNPs, its therapeutic application has been intensively developed in tumour therapy, in recent years. One of the best clinical applications of AuNPs is its use in targeted delivery of anti-cancer drugs. Recent studies have focused on the application of AuNPs to treat melanoma - a malignant neoplasm sourced from melanocytes skin cells - with poor prognosis in advanced stages. Furthermore, early diagnosis can be successfully achieved through utilizing this technique even at early stages with localized distribution. Herein, this study details the previous researches focusing on the use of AuNPs as a novel diagnostic and therapeutic option in management of melanoma.

Ultrahigh sensitive enhanced-electrochemiluminescence detection of cancer biomarkers using silica NPs/graphene oxide: A comparative study.

The increasing progress in using nano-biomaterials for medical purposes has opened new horizons toward researchers around the globe. To investigate the presence of these nanomaterials and the impacts they might have, a comparative enhanced-electrochemiluminescence immunosensing study has been designed. The effects of utilizing graphene oxide, silica, and gold nanoparticles in cancer diagnosis were evaluated during the quantification of two major cancer biomarkers (CEA and AFP) in different approaches. In other words, first and second approaches were designed to employ nanomaterials while third and fourth approaches were developed in absence of those. Accordingly, resulted LODs experienced dramatic amplification when nano-biomaterials were included in the immunosensor modification (for AFP: 1st and 3rd approaches: 1.36fg/ml in comparison with 0.39ng/ml, and for CEA: 2nd and 4th approaches: 1.90fg/ml versus 0.46ng/ml, respectively). Correspondingly, capability of nano-biomaterials for developing highly sensitive and more efficient immunosensors was validated through selectivity, stability, reproducibility, and feasibility examinations.

The antimicrobial effect of lactobacillus casei culture supernatant against multiple drug resistant clinical isolates of Shigella sonnei and Shigella flexneri in vitro.

BACKGROUNDS: Shigellosis remains an important public health problem in developing countries with S. sonnei and S. flexneri in US, Europe and in Asian countries being of importance. OBJECTIVES: This study evaluates the protective effect of Lactobacillus casei cell-free culture supernatants (CFCS) against multiple drug resistance (MDR) clinical samples of Shigella sonnei and Shigella flexneri in vitro. MATERIALS AND METHODS: S. sonnei and S .flexneri was identified by common microbiological and serological methods. Antibiogram with 18 antibiotics were tested for 34 positive cultures by disc diffusion method. The Samples showed considerable resistance to antibiotics. Antimicrobial effects of CFCS were tested against S. sonnei and S. flexneri by agar-well assay and broth micro dilution methods. In addition, the antimicrobial activity remained active treatment after adjust pH 7, adding Proteinase K and heating for L. casei. RESULTS: The results implicate that L. casei strongly inhibits the development of pathogen samples. In contrast, via the disc diffusion method 4 out of 18 antibiogram have shown complete resistance against the pathogen samples. In addition, the natures of antimicrobial properties have been tested in different conditions such as various pH, temperature and presence of proteinase K. The MIC50 (minimum inhibitory concentration) and MIC90 of CFCS of L. casei were determined, for S. sonnei were 2.25 and 10.5, for S .flexneri were 5.25 and 5.25 respectively. The results have shown a significant resistance pattern by these four antibiotics in this case. CONCLUSIONS: The data indicates that. L. casei highly resistant against to antibiotics, heat, Proteinase K and so many activities against MDR Shigella pathogenic strains . L. casei is the best probiotics candidate.